Artificial Heart Market to Reach USD 7.55 Billion by 2032, Fuelled by Rising Prevalence of Heart Failure and Technological Innovations – SNS Insider

By GlobeNewswire On May 26, 2025

U.S. Artificial Heart Market Surges with a Valuation of USD 3.46 Billion by 2032, Driven by Strong Investment in Cardiac Device Innovation & Positive Reimbursement Ecosystem.

Austin, May 26, 2025 (GLOBE NEWSWIRE) — Artificial Heart Market Size & Growth Analysis:

According to SNS Insider, the Artificial Heart Market was valued at USD 2.87 billion in 2023 and is expected to grow to USD 7.55 billion by 2032, expanding at a compound annual growth rate (CAGR) of 11.36% over the forecast period. 2024-2032. The artificial heart market is seeing significant expansion, driven by a rising elderly population, higher prevalence of cardiovascular disorders, and mechanical circulatory support system technical innovations.

Get a Sample Report of Artificial Heart Market@ https://www.snsinsider.com/sample-request/6601

The U.S. Artificial Heart Market was valued at USD 1.43 billion in 2023 and is expected to grow to USD 3.46 billion by 2032 at a CAGR of 10.34% over the forecast period of 2024-2032.

Long-term cardiac support devices are desperately needed since more people suffer from end-stage heart failure, and there is a worldwide scarcity of donor organs. Offering life-saving substitutes for patients waiting for transplants or those disqualified for one, artificial hearts and ventricular assist devices (VADs) are bridging the gap.

Advanced cardiac assist solutions are more important now that chronic heart diseases afflicting over 6.5 million Americans are more common, and heart failure-related hospitalizations are rising. Particularly in the areas of funding, regulatory support, and reimbursement, supportive projects by agencies including the U.S. FDA, the National Institutes of Health (NIH), and the Centers for Medicare & Medicaid Services (CMS) are encouraging invention and accessibility of artificial heart devices all around the country.

The rising prevalence of heart failure, which now affects over 26 million people globally, is driving a worldwide need for artificial hearts. End-stage cardiac disorders have also become more common as lifestyle conditions, including obesity, diabetes, and hypertension, keep growing. Patients who aren’t qualified for transplants now have fresh hope for survival thanks to the availability of advanced left ventricular assist devices (LVADs), biventricular assist devices (BiVADs), and total artificial hearts (TAHs).

Expanding fast is the older population, more susceptible to cardiac failure. The United Nations projects that by 2025, the population 65 years of age and beyond will more than quadruple worldwide, greatly increasing demand for cardiac assist devices. Furthermore, increasing market acceptance is due to developments in minimally invasive insertion techniques, longer device lifetime, and better patient outcomes.

Major Players Analysis Listed in this Report are:

SynCardia Systems, LLC – SynCardia Temporary Total Artificial Heart (TAH)
CARMAT – Aeson Total Artificial Heart
BiVACOR Inc. – BiVACOR Total Artificial Heart
RealHeart – RealHeart TAH
Abbott – HeartMate 3 LVAD
ABIOMED (Johnson & Johnson Services Inc.) – Impella Heart Pump
Jarvik Heart, Inc. – Jarvik 2000 LVAD
LivaNova PLC – Heart-Lung Machine HL 20
Getinge – Cardiohelp System
Terumo Corporation – Capiox Cardiopulmonary Bypass System

Artificial Heart Market Report Scope

Report Attributes	Details
Market Size in 2023	US$ 2.87 billion
Market Size by 2032	US$ 7.55 billion
CAGR	CAGR of 11.36% From 2024 to 2032
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020-2022
Key Regional Coverage	North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)

Segment Analysis

By Type: Left Ventricular Assist Devices (LVADs) Lead with 76.2% Share

LVADs dominated the Artificial Heart Market with 76.2% of the overall market share in 2023. Because LVADs have been so successful in supporting left ventricular function in patients with advanced heart failure, they are increasingly used. Providing long-term cardiac support, they provide both destination therapy and a bridge to a transplant. Modern LVADs are more fit for outpatient treatment since they have evolved with a smaller size, improved battery life, and fewer infection concerns. Major players such as Abbott and Medtronic keep developing their products to increase patient mobility and lifetime, therefore broadening the market.

The Total Artificial Hearts (TAH) segment is also gaining momentum, particularly for patients with biventricular failure. Although the difficulty and hazards of full heart replacement still limit popularity, recent developments in biocompatible materials and better battery life are progressively boosting acceptance.

By Therapy Destination Therapy Emerges as Top Revenue Generator

Driven by increasing acceptability as a permanent treatment choice for patients unfit for transplants, destination therapy held the largest revenue share in 2023. Destination treatment is being recommended more regularly as long-term device management makes healthcare providers more at ease. Advances in telemonitoring and wearable technology also enable real-time performance tracking of the artificial heart, hence improving patient confidence and quality of life.

Traditionally, the most regularly used treatment, bridge-to-transplant therapy, remains very important but is sometimes constrained by donor availability. Strict eligibility requirements and the growing age of transplant candidates have driven more patients onto destination therapy, therefore confirming its predominance as the main therapeutic modality.

Need Any Customization Research on Artificial Heart Market, Enquire Now@ https://www.snsinsider.com/enquiry/6601

Artificial Heart Market Segmentation

By Type

LVADs
Heart-lung machine
Total Artificial Heart

By Therapy

Bridge to transplant
Destination therapy
Bridge to decision
Others

Regional Analysis

The North America region dominated the global Artificial Heart Market with a sizable revenue share in 2023. Robust healthcare infrastructure, increased knowledge, better reimbursement rules, and government funding of cardiovascular innovation all help to drive this supremacy. Additionally, the region is home to Several top artificial heart makers, including SynCardia Systems, Abbott, and Jarvik Heart Inc.

Supported by government-funded healthcare systems and growing clinical studies, the European region is growing significantly. Driven by growing healthcare investments, increased prevalence of cardiovascular disease, and better availability to surgical procedures in nations including India, China, and Japan, the Asia Pacific region is expected to see the fastest growth throughout the projection period.

Recent Improvements

Abbott Laboratories expanded its use to younger patients with FDA clearance in 2023 for pediatric application of the HeartMate 3 LVAD.
To support study on next-generation bioengineered heart pumps, the National Institutes of Health (NIH) announced a USD 25 million grant in 2024.

‘Buy a Single-User PDF of Artificial Heart Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/6601

Table of Contents – Major Key Points

1. Introduction

2. Executive Summary

3. Research Methodology

4. Market Dynamics Impact Analysis

5. Statistical Insights and Trends Reporting

5.1 Incidence and Prevalence of End-Stage Heart Failure (2023), by Region

5.2 Waitlist and Transplant Gap Statistics (2023)

5.3 Healthcare Spending on Mechanical Circulatory Support Devices (2023), by Payer Type (Government, Commercial, Private, Out-of-Pocket)

5.4 Technological Adoption & R&D Pipeline (2023)

5.5 Rehospitalization & Mortality Reduction Trends (2023)

6. Competitive Landscape

7. Artificial Heart Market by Type

8. Artificial Heart Market by Therapy

9. Regional Analysis

10. Company Profiles

11. Use Cases and Best Practices

12. Conclusion

Related Reports

The Cardiac Assist Devices Market size is projected to reach USD 2.24 billion by 2032.

The Ventricular Assist Device Market Size expected to reach USD 3.3 billion by 2032

The Cardiovascular Devices Market is projected to grow at a CAGR of 7.2% during the forecast period of 2024-2032.

The Wearable Cardiac Devices Market size is projected to reach USD 25.71 billion by 2032

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. NewIndiaObserver.com takes no editorial responsibility for the same.